NASDAQ$GDRX
GoodRx Holdings Inc. · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
GoodRx reported Q1 2026 total revenue of $194.0M and net income of $1.2M.
For the quarter ended March 31, 2026, GoodRx generated total revenue of $194.0 million versus $203.0 million a year ago, with prescription transactions revenue lower while pharma manufacturer solutions grew. Net income was $1.2 million (0.6% margin) compared with $11.1 million in Q1 2025; diluted EPS was breakeven at $0.00.
- Total revenue $194.0M; net income $1.2M.
- Prescription transactions revenue $121.8M; pharma solutions $52.2M.
- Share repurchases continued under authorized program.
- Margins compressed on mix and marketing spend.
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$194M
Revenue by segment
GoodRx · $175M total across 3 segments · Q3 2023
- Prescription Transactions$135M+3.2%77.6%
- Subscription$23.2M-12.5%13.3%
- Pharma Direct$15.9M-35.1%9.1%
Forward guidance
Focus on subscription and pharma partner growth, prescription volume, and cost discipline; no numeric EPS guidance in the 10-Q.
Tailwinds
- Remained GAAP profitable despite revenue decline.
- Pharma manufacturer revenue growing.
Headwinds
- Revenue down YoY.
- Net income fell sharply from prior year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro